Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
10/21/2021
Ligand and CR Double-Crane Enter Deal to Develop an Oral COVID-19 Ther...
10/20/2021
CStone Received Chinese IND Acceptance of lorlatinib for ROS1-posit...
10/20/2021
OliX, Pharmaron Agree to Advance Non-clinical Toxicology Testing for ...
10/20/2021
LianBio to Raise up to $345M in Planned IPO at Valuation of $1.8B
10/20/2021
COVID-19 Spurs Growth of China's Domestic Bioprocessing Suppliers: Bio...
10/19/2021
Chipscreen Secures Chinese Approval of Bilessglu (Chiglitazar Sodium t...
10/19/2021
Israel's Silenseed Inks $7.8M Deal with GIBF to Create Chinese JV
10/19/2021
Bridge Biotherapeutics Initiates Phase I Trial for Anti-inflammatory...
10/19/2021
Zai Lab and Entasis Announce Positive Topline Results for Sulbactam-Du...
10/18/2021
CDE Seeks Comments on Draft Chinese Translation of ICH Guideline Q13
10/18/2021
NHC Issues the 14th FYP for National Clinical Specialty Capacity Build...
10/18/2021
WuXi ATU Opens Fourth Manufacturing Facility
10/18/2021
I-Mab Granted IND Approval for P2 Trial of Efineptakin Alfa in Combo w...
10/18/2021
Innovent's P3 Study of Sintilimab for EGFR-Mutated Nonsquamous NSCLC ...
10/18/2021
Forbes: What Can We Learn From the Pharma Manufacturers Leaving China?
10/15/2021
PharmaDJ: September Fundraising Puts Cell Therapy and Immuno-Oncology ...
10/15/2021
CDE Issues the List of Reference Formulations for GQCE Studies (45th B...
10/15/2021
China Issues the Action Plan for Tumor Diagnosis and Treatment Quality...
10/15/2021
CDE Solicits Comments on the Draft Technical Guidelines for Pharmaceut...
10/15/2021
State Council Issues the Implementation Opinion for Promotion of Sanmi...
10/15/2021
Silence Therapeutics Inks Collaboration Deal with Hansoh Pharma
10/15/2021
Gan & Lee Concludes Phase 3 Studies of Biosimilar Insulin Glargine (G...
10/15/2021
Harbour Biomed Begins P3 Study of Hanall's HL161 (batoclimab)
10/15/2021
Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and ...
10/15/2021
Akeso Advances Phase II Trial of IL-4R mAb (AK120) for Atopic Dermatit...
10/15/2021
Shanghai-based Abbisko Makes $200M+ Hong Kong Debut
10/15/2021
Adocia's Partner Tonghua Dongbao Cleared to Start Ultra-Rapid Insulin ...
10/15/2021
Recent Executive Moves
10/15/2021
Takeda Secures New Indication for Takecab as Maintenance Therapy of Re...
10/14/2021
CDE Issues the Technical Guidance for Clinical Research of Anti-HIV Dr...
Page:
165
/
774
Total number of articles:
23208
:
[First]
[<<]
[163]
[164]
[165]
[166]
[167]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit